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summary
Pain is the main manifestation of many rheumatic diseases (be they overtly inflammatory such as rheumatoid 
arthritis or dysfunctional such as fibromyalgia) but, at least initially, the mechanisms involved in the genesis, am-
plification and chronicisation of the persistent pain characterising the various conditions can be very different. The 
main peripheral mechanism underlying acute nociceptive pain is a change in the activity of the nociceptors located 
in the affected anatomical structures (joints, tendons and ligaments), which makes them more sensitive to normally 
painful stimuli (hyperalgesia) or normally non-painful stimuli (allodynia). This physiopathological mechanism of 
peripheral sensitisation plays a primary role in rheumatic diseases characterised by acute inflammation, such as 
the arthritides due to microcrystals. In the case of chronic rheumatic diseases that do not regress spontaneously, 
functional and structural central nervous system changes cause a generalised reduction in the pain threshold that 
is not limited to the anatomical structures involved, thus leading to the appearance of hyperalgesia and allodynia 
in many, if not all body districts. This is the physiopathological basis of chronic, widespread musculoskeletal pain. 
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n	 INTRODUCTION
Musculoskeletal pain is the main reaus-culoskeletal pain is the main reason 
inducing patients to consult a rheumatolo-
gist but, despite this, it was a long time 
before researchers made a serious attempt 
to interpret the physiopathological mecha-
nisms underlying the symptoms. Until a 
few years ago, the pain associated with 
many rheumatic diseases was considered 
to be peripheral in origin and induced by 
the well-known mechanisms of acute or 
chronic inflammation, or morphostructural 
alterations in the involved joints (1-5). This 
interpretation is still supported by many 
rheumatologists despite the repeated clini-
cal evidence of a discrepancy between the 
intensity and characteristics of the pain re-
ported by patients and the extent of the an-
atomical alterations detectable at the sites 
of the perceived pain, as in the case of the 
radiological grading of osteoarthritis (OA) 
(6). Over the last 20 years, the greatest ad-
vances in interpreting musculoskeletal pain 
have been made in the ambit of the wide-
spread extra-articular forms of rheumatism, 
particularly the protypical form of fibromy-
algia (FM) (7-12). Studies of fibromyalgic 
patients have made it possible to recognise 
multiple neurophysiological modifications 
in the perception, transmission and, above 
all, processing of nociceptive afferents 
at the level of the central nervous system 
CNS (13-17). These modifications seem to 
be caused by what has come to be called 
“sensitisation”: i.e. a permanent state of 
neuronal hyperexcitability involving all of 
the peripheral and central structures of the 
nociceptive system (18-23). It has only re-
cently been postulated by some researchers 
that sensitisation of the nociceptive system 
plays a major role in determining the inten-
sity and chronicisation of the pain accom-
panying other rheumatic diseases such as 
OA and rheumatoid arthritis (24-26). 
n	 SENSITISATION OF  
 THE NOCICEPTIVE SYSTEM
The abnormal receptor sensitivity underly-
ing the pain characterising many rheumatic 
diseases causes perceived pain even in the 
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case of the stimulation of low-threshold re-
ceptors whose impulses are transmitted by 
Aβ fibres and, under physiological condi-
tions, generate innocuous sensations. This 
spontaneous clinical pain is not only due 
to early post-translational alterations in 
peripheral nerve endings and the primary 
sensory neurons located in the spinal dor-
sal root ganglia (DRGs), but also to late 
transcriptional changes in the primary sen-
sory neurons and the wide dynamic range 
(WDR) neurons located in the dorsal horn 
of the spinal cord (DHSC) (27, 28).
The result of these processes modifies two 
distinct aspects of sensory neuron function:
•	 basal sensitivity: i.e. the capacity of low-
intensity peripheral stimuli to induce a 
painful sensation (peripheral sensitisa-
tion);
•	 stimulus-induced hypersensitivity: i.e. 
the capacity of peripheral stimuli of par-
ticular intensity and duration to induce 
persistent modifications in the sensitivity 
of the nociceptive system (central sensi-
tisation).
The variations in basal receptor sensitivity 
are largely due to early post-translational 
alterations (27), whereas transcriptional 
changes modify the phenotype of the sen-
sory neurons and make the entire nocicep-
tive system persistently hypersensitive. 
The three processes underlying a wide 
range of chronic inflammatory, neuropathic 
or dysfunctional painful conditions are in-
creased neuronal excitability, structural re-
organisation and reduced inhibition, which 
may occur sequentially or simultaneously.
Peripheral sensitisation
The sensitivity of the peripheral endings of 
nociceptors can be modified by repeated 
mechanical or thermal stimuli or, in the 
case of inflammation, by variations in the 
chemical milieu (29). 
It is widely agreed that peripheral receptor 
sensitisation is the mechanism underlying 
the allodynia and hyperalgesia character-
ising acute inflammatory conditions such 
as the arthritides due to microcrystals, but 
its role in other rheumatic diseases such as 
FM is more controversial. There have long 
been reports of morphological, biochemi-
cal and functional alterations involving 
the peripheral tissues of patients with FM, 
but their significance and specificity have 
never been clarified. The most recent pub-
lished data indicate that the skin biopsies 
of fibromyalgic patients show an increased 
expression of the 2D subunits of N-methyl-
D-aspartate (NMDARs) receptors, inter-
leukin 1 (IL-1), IL-6 and tumour necrosis 
factor alpha (TNFα), and greater mast cell 
infiltration (30-32), and the combination 
of these findings suggest nociceptor sensi-
tisation. Furthermore, in comparison with 
other muscle areas, tender points (TPs) 
have higher concentrations of protons, sub-
stance P (SP), TNFα, IL-1β, serotonin (5-
HT) and norepinephrine (NE), all of which 
are capable of modifying receptor sensitiv-
ity (33, 34).
Central sensitisation
Peripheral sensitisation affects the Aδ and 
C fibres that normally transmit nocicep-
tive stimuli. However, persistent nocicep-
tor stimulation also sensitise the Aβ fibres 
that are not involved in physiological noci-
ception, and induces them to express neu-
ropeptides such as SP and the calcitonin 
gene-related peptide (CGRP), as well as 
neurotrophic factors such as nerve growth 
factor (NGF) and brain-derived neuro-
trophic factor (BDNF) (35). These neuro-
trophins are transported along the fibres 
to the DRGs, where they stimulate the ex-
pression of SP, CGRP and BDNF, which 
are secreted into the DHSC, where many 
of the actions of BDNF are mediated by the 
neurotrophic receptors TrkA and TrkB. As 
NGF regulates the expression of SP, CGRP 
and BDNF, it probably plays a key role in 
neuronal sensitisation (36). 
Central sensitisation can be defined as a 
state of neuronal hyperexcitability in re-
sponse to peripheral stimuli that perma-
nently modifies sensory processes, particu-
larly nociception.
The sensitised neurons are low-threshold 
WDR neurons, and their repeated affer-
ent stimulation by C fibres can lead to a 
series of temporal synaptic summations 
that gradually increase their amplitude and 
discharge frequency (wind-up). Clinically, 
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this gives rise to a sensation of progressive-
ly increasing pain when constantly intense 
stimuli are administered more frequently 
than once every three seconds. 
Glutamate is the most frequent excitatory 
amino acid in the CNS, and its action is 
mediated by many receptors, including 
α-amino-3-hydroxy-5-methyl-4-isoxazo-
lepropionic acid receptors (AMPARs), kai-
nite receptors (KARs), and NMDARs (37).
The role of central sensitisation in the 
pathogenesis of musculoskeletal pain has 
been widely studied in patients with FM, 
whose cerebrospinal fluid (CSF) contains 
increased levels of SP (38, 39), glutamate 
(40) and NGF (41), and reduced levels 
of glial cell-derived neurotrophic factor 
(GDNF) (42), a substance with antinoci-
ceptive activity at the level of the DHSC 
that is probably mediated by the inhibition 
of SP release and the expression of sodi-
um channel subunits. Glutamate, SP and 
NGF induce the wind-up of WDR neurons, 
whereas GDNF inhibits it. 
n	 THE ROLE OF THE  
 DESCENDING MODULATORY  
 PATHWAYS
Spinal cord WDR neurons are not only 
sensitised by nociceptive stimuli coming 
from the periphery, but also by the disinhi-
bition or stimulation of regulatory tone. As 
this is normally provided by the pathways 
descending from the supraspinal centres, 
which the endogenous opioids, 5-HT and 
NE as neurotransmitters (43), it is possible 
that the algogenic threshold is modified as 
a result of facilitating activity originating 
from them (for, example under conditions 
of stress or hypervigilance), or because of 
a reduction in inhibitory activity. 
It is thought that the descending control 
system of nociceptive afferents underlies 
various phenomena related to the experi-
ence of pain depending on its inhibitory or 
facilitating action, including the placebo 
effect, stress-induced analgesia, anticipa-
tory hyperalgesia, and the clinical response 
to cognitive-behavioural therapies.
Functional nuclear magnetic resonance 
(fNMR) studies have shown that a noci-
ceptive pressor stimulus causes greater 
activation of the anterior cingulated cortex 
(ACC), periaqueductal grey matter (PAG), 
and dorso-lateral prefrontal cortex (DLP-
FC) in patients with OA than in controls 
(44). As the facilitating descending fibres 
of the nociceptive pathways originate from 
the ACC, it is thought that pain in OA pa-
tients is partially mediated by excessive 
facilitating activity. Furthermore, the fact 
that the pressor stimulation threshold is not 
increased by the experimental application 
of a nociceptive stimulus suggests a func-
tional deficit in the diffuse noxious inhibi-
tory control (DNIC) system (45).
n	 INTERACTIONS BETWEEN  
 THE IMMUNE AND NERVOUS  
 SYSTEMS
Although pain is a sensation processed by 
the CNS, the immune system, astrocytes 
and microglia may contribute to the pro-
cess of sensitisation and the consequent 
development of chronic pain. An emerg-
ing concept is that immune cells, glial cells 
and sensitive neurons form an integrated 
network in which activation of the immune 
system is capable of modifying the excit-
ability of the nociceptive pathways.
Activated resident immune cells, such as 
mast cells, macrophages and dendritic 
cells, intervene in the early phases of pe-
ripheral sensitisation by releasing chemo-
kines, complement factors (C3a and C5a) 
and vasoactive amines; subsequently, the 
monocytes and T lymphocytes that accu-
mulate at the sites of tissue damage release 
pro-inflammatory cytokines, such as IL-1β 
and TNF-α that contribute to receptor sen-
sitisation.
Astrocytes and activated glial cells may 
play a role in the centrally sensitising no-
ciceptive pathways and amplify pain by 
releasing glutamate and D-serine, which 
activate NMDARs at neuronal level, or 
by inducing the collateral sprouting of the 
nerve endings of the Aβ fibres in laminae 
III and IV of the DHSC in order to form 
new synapses with the secondary neurons 
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of laminae I and II (46). Consequently, un-
der conditions of chronic pain, the changes 
in the pain matrix are both functional and 
structural.
n	 THE ROLE OF  
 THE AUTONOMOUS  
 NERVOUS SYSTEM 
The role of the autonomous nervous sys-
tem (ANS) in the genesis and chronicisa-
tion of pain has been widely documented 
in a series of clinical conditions known as 
“reflex sympathetic dystrophy” until the 
mid-1940s, but more recently called “com-
plex regional pain syndrome” (47, 48).
Many painful neuropathic conditions arise 
after partial lesions of the peripheral ner-
vous system. In experimental animal mod-
els involving partial nerve trunk lesions, 
the primary sensory neurons underlying 
the lesioned fibre and those underlying fi-
bres unaffected by the lesion both acquire 
a de novo capacity to express genes, thus 
changing their phenotype. In combination 
with other soluble and diffusible factors 
such as IL-1β and TNF-α, tissue growth 
factors such as NGF not only sensitise the 
receptors, but also generate ectopic activ-
ity (49). One example is the induction or 
up-regulation of catecholamine receptors 
at the level of undamaged nociceptors; un-
der these conditions, the nociceptors are 
activated by NE and the consequent neu-
ropathic pain has been defined as “pain 
sustained by the sympathetic system” (50). 
An inversion in the phenotypical shift is as-
sociated with a reduction in pain intensity, 
and so it is hoped that identifying the vari-
ous diffusible factors that modulate gene 
expression at the level of the DRGs will al-
low the development of directed therapies 
that are more efficacious than those cur-
rently available (51-53). 
n	 THE ROLE OF PERIPHERAL  
 TISSUES
However, while recognising the nervous 
system as the principal factor determin-
ing pain duration and intensity, we should 
not forget the role of the peripheral tissues 
from which the nociceptive inputs initially 
originate because the maintenance of cen-
tral sensitisation in any case requires the 
contribution of albeit moderately intense 
peripheral tonic impulses (54). Lidocaine 
infiltrations of TPs at the level of the tra-
pezius muscle in FM patients raises the 
nociceptive threshold not only in the in-
filtrated area (primary hyperalgesia), but 
also in distant sites such as the forearm 
(secondary hyperalgesia) (55). Kosek has 
demonstrated that the neurophysiological 
modifications indicating central sensitisa-
tion during the course of OA (alterations in 
the DNIC system, secondary hyperalgesia, 
and the presence of more extensive recep-
tive fields) normalise after the prosthetic 
replacement of the joint involved (25). 
The therapeutic approach to many diseases 
of the musculoskeletal apparatus should 
therefore also take into account the role of 
peripheral tissues in the genesis and main-
tenance of pain.
n	 THE ROLE OF THE STRESS  
 REACTION SYSTEM
The clinical observation that, like that 
of other central sensitisation syndromes 
such as chronic headache, irritable bowel 
syndrome and temporo-mandibular disor-
ders, the onset of FM often coincides with 
physically or mentally stressing events has 
led some authors to include it in the spec-
trum of stress-related diseases (56-62). 
Furthermore, there is evidence that many 
of the neuroendocrine pathways involved 
in the reaction to stress show more or less 
marked functional alterations in fibromy-
algic patients (63, 64). It also seems that 
persistently high cortisol levels, such as 
those encountered in situations of chronic 
stress, cause quantitative alterations in the 
expression of adrenergic and dopaminergic 
receptors, and qualitative alterations in the 
subunit composition of GABA and aspartic 
acid receptors (NMDARs), and that such 
alterations underlie the hyper-reactivity of 
the CNS to external stimuli. 
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Furthermore, it has been recently demon-
strated in experimental animal models that 
stressful situations are capable of signifi-
cantly modifying the transduction sensitiv-
ity of muscle nociceptors, thus inducing 
peripheral sensitisation (65). 
It is therefore likely that, by causing chang-
es in the stress response system and, conse-
quently, neuroendocrine dysfunctions and 
quantitative and qualitative alterations in 
the receptor systems involved in nocicep-
tion, external traumatic factors predispose 
at least a subgroup of patients to the adult 
development of many chronic painful syn-
dromes.
n	 THE ROLE OF GENETICS
It is known that sensitivity to pain varies 
widely in different breeds of rodents, and 
similar variability also exists among hu-
mans (66, 67). Population studies have 
demonstrated that 50% of chronic pain is 
inheritable, and it has been estimated that 
the role of inheritance is 29% in the ab-
sence of pain and 44% in the case of se-
vere pain. Even after correcting the data 
for confounding factors such as age, body 
mass index, gender, income, occupation, 
physical activity levels and family habits, 
inheritance has a weight of 30% in deter-
mining severe chronic pain (68). 
It has long been known that genetic muta-
tions in a specific subunit of sodium chan-
nels known as NAV 1.7 cause rare genetic 
diseases characterised by opposite distur-
bances: very intense pain in the case of fa-
milial erythromelalgia and paroxysmal ex-
treme pain disorder, or complete insensitiv-
ity to pain (69-70). Mutations in the gene 
encoding sodium channels can also explain 
the presence of chronic pain (particularly 
neuropathic pain) in much more frequent 
clinical conditions such as peripheral neu-
ropathies (71).
Various studies have demonstrated the im-
portance of genetic factors in causing FM, 
the rheumatic disease that is prototypical of 
chronic musculoskeletal pain (72), particu-
larly polymorphisms of the genes encoding 
the enzymes and/or receptors involved in 
the metabolism and transport of mono-
amines, the mediators that play a critical 
role in sensory processes and stress respons-
es (Tab. I). It has more recently been shown 
that these polymorphisms are not specific 
to FM but also play a role in causing many 
other chronic painful conditions. In a large 
series of patients with hip OA, van Meurs 
et al. found that the presence of the 158Met 
variant of catechol-O-methyltransferase 
(COMT) triples the risk of developing pain 
regardless of its radiological grading (73). 
n	 THE ROLE OF  
 THE EMOTIONAL-COGNITIVE  
 FILTER
Depression is a common denominator of 
chronic painful conditions (74-77), but the 
relationship between pain and depression 
seems to be bi-directional: chronic depres-
sion can induce central sensitisation and 
lower the nociceptive threshold, and chron-
ic pain can be associated with changes in 
character that can reach the point of depres-
sion. Furthermore, of the three symptom-
atological clusters of depression (affective, 
cognitive and somatic), the somatic cluster 
includes physical symptoms that overlap 
those of many chronic, dysfunctional and 
painful syndromes (headache, low back 
pain, and aspecific visceral pains). This 
parallelism leads to pathogenetic situations 
in which there is both depression and pain 
not only at neurotransmitter level, but also 
at the level of the hormonal, immunologi-
cal and neurotrophic systems. In particular, 
the changes in neurotropin levels encoun-
Table I - Genetic markers of fibromyalgia.
system Genetic markers
Serotoninergic
Polymorphism of the serotonin 
5-HT2A receptor (phenotype T/T)
Polymorphism of the promoter 
region of the serotonin 
transporter (5-HTTLPr)
Dopaminergic Polymorphism of the dopamine D4 receptor
Catecholaminergic
Polymorphism of the catechol-O- 
methyl transferase (COMT) 
emzyme
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tered in chronic pain conditions also lead to 
neurodegenerative phenomena, such as the 
neuronal apoptosis and reduced hippocam-
pal volume observed in patients affected 
by depression (78). In addition to the pre-
viously mentioned facilitation of collateral 
Aβ fibre sprouting and neosynaptogenesis, 
the secretion of IL-1β and TNFα by acti-
vated microglia activates the indoleamine 
2,3 dioxygenase enzyme that converts 
tryptophan into kynurenine, thus interfer-
ing with the synthesis of 5-HT and giving 
rise to depressive symptoms (79). Finally, 
the processing of nociceptive stimuli at the 
level of the medial prefrontal cortex is in-
creased in depressed subjects, which seems 
to explain the discrepancy between detect-
able morphostructural damage and the pain 
perceived by depressed subjects who are 
also affected by one of the many highly 
prevalent diseases of the musculoskeletal 
apparatus such as low back pain or OA.
n	 THE ROLE OF COGNITIVE- 
 BEHAVIOURAL VARIABLES
Despite our increasing knowledge of the 
mechanisms governing various sensory 
processes, including nociception, many 
aspects of the pain characterising most 
rheumatic diseases have not yet been fully 
clarified. The experience of pain is a re-
sult of the intersection of multiple biologi-
cal, environmental, social, cultural, racial, 
cognitive and behavioural variables that 
underline the uniqueness of individual 
patients not only in terms of the clinical 
manifestations of their symptoms, but also 
in terms of their responses to treatment. 
The significance attributed to pain in the 
context of personal experience contributes 
to determining the behavioural strategy 
adopted by patients in order to cope with 
their condition: subjects with a high sense 
of self-efficacy (which can be defined as an 
awareness of being capable of confronting 
a changed external situation) tend to use 
active coping behaviours until they have 
successfully reached their goal, whereas 
those with a low sense of self-efficacy soon 
discontinue coping strategies because they 
expect them to fail. This maladaptive style 
of confronting one’s situation is known as 
“abnomal illness behaviour” and defined 
as “mislearning how to perceive, evaluate 
and act in relation to one’s state of health” 
(80, 81). Maladaptive coping affects the 
intensity of subjective pain and the global 
impact of a disease (82, 83), which is why 
the discordance between the degree of dis-
ability reported by patients and that mea-
sured by means of specific questionnaires 
is greater in patients with FM than in those 
affected by other rheumatic diseases such 
as RA (84, 85). Hypervigilance (paying 
greater attention to both intero- and extero-
ceptive stimuli) can also be considered a 
maladaptive model that leads to a percep-
tive style of amplifying sensations, includ-
ing nociception (86).
Another model that can help us to under-
stand the cause of the chronicisation of 
musculoskeletal pain is that called “fear-
avoidance” by Lethem in 1983 (87). The 
central concept underlying this model is 
the fear of pain, which leads to the two 
extreme responses of confrontation and 
flight. Confrontation (i.e. the activation of 
active coping mechanisms) will eventually 
lead to strategies aimed at reducing pain-
ful symptoms, whereas flight will tend to 
exacerbate the fear until, in extreme cases, 
it leads to the onset of an outright phobia 
(88).
n	 CONCLUSIONS
The physiopathological mechanisms un-
derlying musculoskeletal pain have been 
sufficiently clarified in some clinical con-
ditions characterised by acute inflamma-
tion, such as the inflammatory poussès of 
the arthritides due to microcrystals. It is 
more difficult to understand the causes of 
the chronic musculoskeletal pain that does 
not seem to be caused simply by persistent 
activation of peripheral nociceptors, but 
by changes in the sensitivity of the noci-
ceptive system as a whole (peripheral and 
central) in genetically predisposed sub-
jects, a pathogenetic interpretation that has 
been widely studied in algodysfunctional 
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syndromes, particularly FM, over the last 
twenty years.
Much more recent is the recognition that 
the neurophysiological mechanisms un-
derlying central sensitisation syndromes 
may also play a role in causing the painful 
symptoms characterising rheumatic dis-
eases, which were previously considered to 
be peripheral in origin. Neurophysiological 
alterations compatible with the sensitisa-
tion of both the peripheral and central noci-
ceptive pathways have been demonstrated 
not only in RA, but also in highly prevalent 
conditions such as OA and aspecific low 
back pain. 
Finally, the induction of peripheral receptor 
sensitisation in situations of psychological 
stress supports the hypothesis that, regard-
less of the underlying rheumatic disease, 
the chronicisation of pain is due to the in-
teraction of neurohysiological (neuroplas-
ticity), psychological (anxiety/depression) 
and social factors (familial and working 
support, income, etc.) (89, 90).
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